GLPG
Galapagos NV ADRNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$1.94B
P/E Ratio
5.18
EPS
$5.58
Beta
0.15
52W High
$37.78
52W Low
$23.29
50-Day MA
$32.83
200-Day MA
$32.22
Dividend Yield
—
Profit Margin
28.80%
Forward P/E
303.03
PEG Ratio
0.00
About Galapagos NV ADR
Galapagos NV, a clinical-stage biotechnology company, discovers, develops and markets several small molecule drugs. The company is headquartered in Mechelen, Belgium.
Fundamentals
| Revenue (TTM) | $1.11B |
| Gross Profit (TTM) | $623.09M |
| EBITDA | $568.17M |
| Operating Margin | 88.00% |
| Return on Equity | 10.40% |
| Return on Assets | 8.87% |
| Revenue/Share (TTM) | $0.84 |
| Book Value | $56.83 |
| Price-to-Book | 0.52 |
| Price-to-Sales (TTM) | 1.75 |
| EV/Revenue | 1.184 |
| EV/EBITDA | -31.50 |
| Quarterly Earnings Growth (YoY) | 3036.00% |
| Quarterly Revenue Growth (YoY) | 1093.00% |
| Shares Outstanding | $65.90M |
| Float | $44.54M |
| % Insiders | 25.35% |
| % Institutions | 22.61% |
Analyst Ratings
Consensus ($28.39 target)
3
HoldData last updated: 4/8/2026